{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:50:55Z","timestamp":1770907855935,"version":"3.50.1"},"reference-count":47,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Bayer, Takeda, GlaxoSmithKline, Bristol-Myers Squibb and Arqule"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,4,30]]},"DOI":"10.2217\/fon.14.318","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T14:55:46Z","timestamp":1427986546000},"page":"1223-1232","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Targeted Therapy for Thymic Epithelial Tumors: A New Horizon? Review of the Literature and Two Cases Reports"],"prefix":"10.1080","volume":"11","author":[{"given":"Matteo","family":"Simonelli","sequence":"first","affiliation":[{"name":"Humanitas Cancer Center, Oncology &amp; Hematology Unit, Istituto Clinico Humanitas IRCCS, 20089RozzanoMI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo A","family":"Zucali","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, Oncology &amp; Hematology Unit, Istituto Clinico Humanitas IRCCS, 20089RozzanoMI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo B","family":"Suter","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, Oncology &amp; Hematology Unit, Istituto Clinico Humanitas IRCCS, 20089RozzanoMI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Lorenzi","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, Oncology &amp; Hematology Unit, Istituto Clinico Humanitas IRCCS, 20089RozzanoMI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Rubino","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, Oncology &amp; Hematology Unit, Istituto Clinico Humanitas IRCCS, 20089RozzanoMI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fatuzzo","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, Oncology &amp; Hematology Unit, Istituto Clinico Humanitas IRCCS, 20089RozzanoMI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Alloisio","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, Thoracic Surgery Unit, Istituto Clinico Humanitas IRCCS, 20089Rozzano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, Oncology &amp; Hematology Unit, Istituto Clinico Humanitas IRCCS, 20089RozzanoMI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1f62d"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2003.10.001"},{"key":"e_1_3_2_5_1","first-page":"146","volume-title":"World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart","author":"Kuo TT","year":"2004","unstructured":"Kuo TT . Tumours of the thymus. In: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. TravisWD, BrambillaE, Muller-HermelinkHKet al. (Eds). IARC Press, Lyon, France, 146\u2013248 (2004)."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-009-0083-7"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0487"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyl028"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-004-0545-z"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.03.013"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.01.009"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20811"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70141-9"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.2741\/2098"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gef\u0131tinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup A","year":"2005","unstructured":"Kurup A , BurnsM, DropchoSet al. Phase II study of gef\u0131tinib treatment in advanced thymic malignancies. J. Clin. Oncol.23(Suppl.), Abstract 7068 (2005).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A Phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano PM","year":"2008","unstructured":"Bedano PM , PerkinsS, BurnsMet al. A Phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J. Clin. Oncol.26, S713(Suppl.), Abstract 19087 (2008).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2003.01663.x"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.05.108"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0644"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1514"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200406173502523"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181a52e25"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f209b9"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.6427"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr626"},{"key":"e_1_3_2_27_1","volume-title":"44th American Society of Clinical Oncology","author":"Salter JT","year":"2008","unstructured":"Salter JT , LevisD, YannoutsosCet al. Imatinib for the treatment of thymic carcinoma. Presented at: 44th American Society of Clinical Oncology. Chicago, IL, USA, 30 May\u20133 June 2008."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181b6be57"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1690-0"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aanat.2007.05.003"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2002.124389"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005950170021"},{"key":"e_1_3_2_33_1","volume-title":"44th American Society of Clinical Oncology","author":"Isambert N","year":"2008","unstructured":"Isambert N , FreyerG, ZanettaSet al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. Presented at: 44th American Society of Clinical Oncology. Chicago, IL, USA, 30 May\u20133 June 2008."},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-008-9100-0"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.09.011"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-012-0235-8"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq313"},{"key":"e_1_3_2_38_1","volume-title":"50th American Society of Clinical Oncology","author":"Thomas A","year":"2014","unstructured":"Thomas A , RajanA, BermanAWet al. Phase II trial of sunitinib in patients with thymic epithelial tumors (TET). Presented at: 50th American Society of Clinical Oncology. Chicago, IL, USA, 30 May\u20133 June 2014."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181e392a8"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25367"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1118"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903055049"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70596-5"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1786"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4467"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0766"},{"key":"e_1_3_2_47_1","volume-title":"50th American Society of Clinical Oncology","author":"Zucali PA","year":"2014","unstructured":"Zucali PA , De PasG, PalmieriGet al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. Presented at: 50th American Society of Clinical Oncology. Chicago, IL, USA, 30 May\u20133 June 2014."},{"key":"e_1_3_2_48_1","volume-title":"50th American Society of Clinical Oncology","author":"Besse B","year":"2014","unstructured":"Besse B , GarassinoMC, RajanAet al. A Phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). Presented at: 50th American Society of Clinical Oncology. Chicago, IL, USA, 30 May\u20133 June 2014."},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.10.016"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.14.318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:04Z","timestamp":1719125104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.14.318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,4,30]]}},"alternative-id":["10.2217\/fon.14.318"],"URL":"https:\/\/doi.org\/10.2217\/fon.14.318","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}